Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7419)
All Articles published online
|
Publishing Process of This Article
|
Jan 21, 2014 (publication date) through Dec 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794 [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i3/786.htm |
| Number | Citing Articles |
| 1 |
Jae Jin Lee, Martine Extermann. Cancer and Chronic Conditions. 2016; : 131 doi: 10.1007/978-981-10-1844-2_5
|
| 2 |
G. de Stefano, V. Iodice, N. Farella. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report. Journal of Gastrointestinal Cancer 2015; 46(4): 430 doi: 10.1007/s12029-015-9720-5
|
| 3 |
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi, Andrea Lorenzo Inghilesi. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World Journal of Hepatology 2015; 7(8): 1041-1053 doi: 10.4254/wjh.v7.i8.1041
|
| 4 |
Xue-Fen Lei, Yang Ke, Tian-Hao Bao, Hao-Ran Tang, Xue-Song Wu, Zhi-Tian Shi, Jie Lin, Zhi-Xian Zhang, Hou Gu, Lin Wang. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World Journal of Clinical Cases 2018; 6(5): 74-83 doi: 10.12998/wjcc.v6.i5.74
|
| 5 |
Gennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, Emanuela Ferraro, Antonio Mazzocca, Ferruccio De Rose, Gianfranco Filippelli, Ines Abbate, Mario Brandi. Sorafenib: 10 years after the first pivotal trial. Future Oncology 2015; 11(13): 1863 doi: 10.2217/fon.15.85
|
| 6 |
Thomas Reiberger, Yunching Chen, Rakesh R Ramjiawan, Tai Hato, Christopher Fan, Rekha Samuel, Sylvie Roberge, Peigen Huang, Gregory Y Lauwers, Andrew X Zhu, Nabeel Bardeesy, Rakesh K Jain, Dan G Duda. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nature Protocols 2015; 10(8): 1264 doi: 10.1038/nprot.2015.080
|
| 7 |
Yadi Liao, Yun Zheng, Wei He, Qijiong Li, Jingxian Shen, Jian Hong, Ruhai Zou, Jiliang Qiu, Binkui Li, Yunfei Yuan. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncology Letters 2017; 13(2): 984 doi: 10.3892/ol.2016.5525
|
| 8 |
Seong K. Na, Sun Y. Yim, Sang J. Suh, Young K. Jung, Ji H. Kim, Yeon S. Seo, Hyung J. Yim, Jong E. Yeon, Kwan S. Byun, Soon H. Um. ALBI versus Child‐Pugh grading systems for liver function in patients with hepatocellular carcinoma. Journal of Surgical Oncology 2018; 117(5): 912 doi: 10.1002/jso.24992
|
| 9 |
Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Ming‐Yen Hsieh, Nei‐Jen Hou, I‐Hung Lin, Po‐Cheng Liang, Yi‐Shan Tsai, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. The Kaohsiung Journal of Medical Sciences 2019; 35(10): 624 doi: 10.1002/kjm2.12105
|
| 10 |
Federica Cosso, Daniele Lavacchi, Sara Fancelli, Enrico Caliman, Marco Brugia, Gemma Rossi, Costanza Winchler, Serena Pillozzi, Lorenzo Antonuzzo. Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer. Anti-Cancer Drugs 2023; 34(3): 451 doi: 10.1097/CAD.0000000000001410
|
| 11 |
Wen‐Tsan Chang, Sheng‐Nan Lu, Kung‐Ming Rau, Ching‐Shan Huang, King‐Teh Lee. Increased cumulative doses and appearance of hand‐foot skin reaction prolonged progression free survival in sorafenib‐treated advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences 2018; 34(7): 391 doi: 10.1016/j.kjms.2018.03.006
|
| 12 |
Brittany Dewdney, Alexandra Roberts, Liang Qiao, Jacob George, Lionel Hebbard. A Sweet Connection? Fructose’s Role in Hepatocellular Carcinoma. Biomolecules 2020; 10(4): 496 doi: 10.3390/biom10040496
|
| 13 |
Sae Hwan Lee, Il Han Song, Ran Noh, Ha Yan Kang, Suk Bae Kim, Soon Young Ko, Eoum Seok Lee, Seok Hyun Kim, Byung Seok Lee, An Na Kim, Hee Bok Chae, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Jae Dong Lee, Heon Young Lee. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1273-2
|
| 14 |
Shijie Wang, Yiting Wang, Jiangtao Yu, Huaxing Wu, Yanming Zhou. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers 2022; 14(22): 5525 doi: 10.3390/cancers14225525
|
| 15 |
Céline Lescure, Florian Estrade, Maud Pedrono, Boris Campillo-Gimenez, Samuel Le Sourd, Marc Pracht, Xavier Palard, Héloïse Bourien, Léa Muzellec, Thomas Uguen, Yan Rolland, Etienne Garin, Julien Edeline. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers 2021; 13(15): 3794 doi: 10.3390/cancers13153794
|
| 16 |
Parakh Gulati, Sunil Taneja, Ajay Duseja, Virendra Singh. Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Should we extend the boundaries?. Hepatology 2022; 76(4): E80 doi: 10.1002/hep.32554
|
| 17 |
Daniele Lavacchi, Giandomenico Roviello, Alessia Guidolin, Silvia Romano, Jacopo Venturini, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Elisa Pellegrini, Marco Brugia, Serena Pillozzi, Lorenzo Antonuzzo. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. International Journal of Molecular Sciences 2023; 24(6): 5840 doi: 10.3390/ijms24065840
|
| 18 |
Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatology Research 2015; 45(10) doi: 10.1111/hepr.12480
|
| 19 |
Xuying Wan, Xiaofeng Zhai, Zhenlin Yan, Pinghua Yang, Jun Li, Dong Wu, Kui Wang, Yong Xia, Feng Shen. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget 2016; 7(50): 83806 doi: 10.18632/oncotarget.11514
|
| 20 |
Lei Xu, Lin Chen, Bin Zhang, Zhicheng Liu, Qiumeng Liu, Huifang Liang, Yifa Chen, Xiaoping Chen, Chao Leng, Bixiang Zhang. Alkaline phosphatase combined with γ-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1115706
|